# South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

> **NCT05682131** · PHASE4 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 210 (estimated)

## Conditions studied

- Arsenic Trioxide
- Childhood ALL

## Interventions

- **DRUG:** Realgar Indigo naturalis formula
- **COMBINATION_PRODUCT:** Conventional chemotherapy

## Key facts

- **NCT ID:** NCT05682131
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-27
- **Primary completion:** 2027-09-27
- **Final completion:** 2030-09-27
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2023-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682131, "South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05682131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*